888-998-0576 info@papausa.com

FDA approves hepatitis C drugs

FDA  Approves First Treatment for Tardive Dyskinesia: Valbenazine (Ingrezza)

UPDATED April 11, 2017 // The U.S. Food and Drug Administration approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition.

Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. Some affected people also experience involuntary movement of the extremities or difficulty breathing.

“Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness,” said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition.”

The efficacy of Ingrezza was shown in a clinical trial of 234 participants that compared Ingrezza to placebo. After six weeks, participants who received Ingrezza had improvement in the severity of abnormal involuntary movements compared to those who received placebo.

Adverse Effects:     

Ingrezza may cause serious side effects including sleepiness and heart rhythm problems (QT prolongation).

  • Its use should be avoided in patients with congenital long QT syndrome or with abnormal heartbeats associated with a prolonged QT interval.
  • Those taking Ingrezza should not drive or operate heavy machinery or do other dangerous activities until it is known how the drug affects them.
This Post Has One Comment

Leave a Reply

Your email address will not be published. Required fields are marked *